UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer

Current oncology reports, 2022, Vol.24 (1), p.113-123

2022

Volltextzugriff (PDF)

MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate

Cancer cell, 2020-07, Vol.38 (1), p.60-78.e12

2020

Volltextzugriff (PDF)

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Drugs in Context, 2020-01, Vol.9, p.1-11

2020

Volltextzugriff (PDF)

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC

Clinical cancer research, 2018-12, Vol.24 (24), p.6195-6203

2018

Volltextzugriff (PDF)

Locally Advanced, Unresectable Non-Small Cell Lung Cancer

Current oncology reports, 2020-04, Vol.22 (4), p.31-31, Article 31

2020

Volltextzugriff (PDF)

A matching-based machine learning approach to estimating optimal dynamic treatment regimes with time-to-event outcomes

Statistical methods in medical research, 2024-05, Vol.33 (5), p.794-806

2024

Volltextzugriff (PDF)

Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data

Cancers, 2022-01, Vol.14 (3), p.690

2022

Volltextzugriff (PDF)

Editorial: Update on the Biology, Management, and Treatment of Small Cell Lung Cancer

Frontiers in oncology, 2020-11, Vol.10, p.1783-1783

2020

Volltextzugriff (PDF)

Subcutaneous metastasis from recurrent basaloid squamous cell carcinoma of the esophagus

Journal of oncology pharmacy practice, 2019-03, Vol.25 (2), p.492-496

2019

Volltextzugriff (PDF)

Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer

Cancer treatment and research communications, 2023, Vol.35, p.100686-100686, Article 100686

2023

Volltextzugriff (PDF)

Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors

Supportive care in cancer, 2018-08, Vol.26 (8), p.2911-2918

2018

Volltextzugriff (PDF)

Inpatient Smoking Cessation Counseling and Pharmacotherapy: A Practice Gap

Chest, 2015-10, Vol.148 (4), p.1074A-1074B

2015

Volltextzugriff (PDF)

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden

Journal for immunotherapy of cancer, 2023-08, Vol.11 (8), p.e007440

2023

Volltextzugriff (PDF)

524 A phase 2, multi-arm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A554-A554

2021

Volltextzugriff (PDF)

Pericardial synovial sarcoma: challenges in diagnosis and management

F1000 research, 2014, Vol.3, p.15-15

2014

Volltextzugriff (PDF)

Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2022-02, Vol.40 (6), p.576-585

2022

Volltextzugriff (PDF)

An update on newer monoclonal antibodies in lymphoma therapy

Asian Journal of Oncology, 2016-01, Vol.2 (1), p.003-007, Article 003

2016

Volltextzugriff (PDF)

Race‐inclusive and equitable access to immune checkpoint inhibitor therapy: What are the biggest hurdles?

Cancer, 2023-12, Vol.129 (23), p.3692-3693

2023

Volltextzugriff (PDF)

Clinical outcomes with frontline immunotherapy (IO) in BRAF-mutant NSCLC

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e21089-e21089

2023

Volltextzugriff (PDF)

Letter by Puri et al Regarding Article, “Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control”

Circulation (New York, N.Y.), 2017-05, Vol.135 (19), p.e1039-e1040

2017

Volltextzugriff (PDF)

Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib

Clinical lung cancer, 2023-06, Vol.24 (4), p.360-361

2023

Volltextzugriff (PDF)

PP01.35 Serplulimab vs atezolizumab added to chemotherapy in patients with treatment-naive ES-SCLC in the United States – ASTRIDE Trial in Progress

Journal of thoracic oncology, 2024-07, Vol.19 (7), p.e20-e21

2024

Volltextzugriff (PDF)

Diagnostic performance of Cu64-dotatate-PET/CT or Ga68-dotatate-PET/CT with 18F-fluorodeoxyglucose (FDG)-PET/CT for neuroendocrine tumor evaluation

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e16285-e16285

2024

Volltextzugriff (PDF)

The association between body composition, quality of life (QoL), overall survival (OS) and decision to treat (DTT) in patients with metastatic non–small cell lung cancer (mNSCLC)

Journal of clinical oncology, 2022-10, Vol.40 (28_suppl), p.377-377

2022

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer

Current treatment options in oncology, 2018-08, Vol.19 (8), p.39-17, Article 39

2018

Volltextzugriff (PDF)

1 – 25 von 93

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(78)

Publikationsform

Sprache

Englisch
(93)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(31)
Science & Technology
(31)
Oncology
(25)
Humans
(20)
Lung Cancer
(13)
Chemotherapy
(10)
Immunotherapy
(9)
Lung Neoplasms - Genetics
(8)
Carcinoma, Non-Small-Cell Lung - Genetics
(7)
Mutation
(7)
Patients
(7)
Aged
(6)
Male
(6)
Metastasis
(6)
Non-Small Cell Lung Carcinoma
(6)
Biomarkers
(5)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Lung Neoplasms - Drug Therapy
(5)
Lung Neoplasms - Pathology
(5)
Metastases
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer

MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC

Locally Advanced, Unresectable Non-Small Cell Lung Cancer

A matching-based machine learning approach to estimating optimal dynamic treatment regimes with time-to-event outcomes

Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data

Editorial: Update on the Biology, Management, and Treatment of Small Cell Lung Cancer

Subcutaneous metastasis from recurrent basaloid squamous cell carcinoma of the esophagus

Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer

Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors

Inpatient Smoking Cessation Counseling and Pharmacotherapy: A Practice Gap

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden

524 A phase 2, multi-arm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors

Pericardial synovial sarcoma: challenges in diagnosis and management

Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung Cancer

An update on newer monoclonal antibodies in lymphoma therapy

Race‐inclusive and equitable access to immune checkpoint inhibitor therapy: What are the biggest hurdles?

Clinical outcomes with frontline immunotherapy (IO) in BRAF-mutant NSCLC

Letter by Puri et al Regarding Article, “Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control”

Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib

PP01.35 Serplulimab vs atezolizumab added to chemotherapy in patients with treatment-naive ES-SCLC in the United States – ASTRIDE Trial in Progress

Diagnostic performance of Cu64-dotatate-PET/CT or Ga68-dotatate-PET/CT with 18F-fluorodeoxyglucose (FDG)-PET/CT for neuroendocrine tumor evaluation

The association between body composition, quality of life (QoL), overall survival (OS) and decision to treat (DTT) in patients with metastatic non–small cell lung cancer (mNSCLC)

Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer

Suchergebnisse filtern